Improved breast cancer care by innovative diagnostic test MammaPrint

Projektinformationen

MammaPrint

ID Finanzhilfevereinbarung: 672570

DOI 10.3030/672570

Abgeschlossenes Projekt

EK-Unterschriftsdatum 10 Juni 2015

Startdatum 1 Juli 2015

Enddatum 31 Dezember 2018

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 4 048 407,00

EU-Beitrag € 4 048 407,00

Koordiniert durch

AGENDIA NV
Netherlands

Ziel

Agendia NV, a Dutch SME, was founded in 2003 as spin-off from the Netherlands Cancer Institute. They pursue the commercialization of molecular diagnostics using DNA microarray technology for cancer. Agendia aims to be one of the key market players in genomic breast cancer profiling. One of the products Agendia is developing is MammaPrint, a breast cancer recurrence test. This test identifies the risk of recurrence of cancer after surgical treatment, so that the appropriate adjuvant treatment can be selected personalized on the patients tumor characteristics.

Breast cancer is the most commom cancer in the world and the principle cause of death of cancer among women worldwide. Currently guidelines recommend that adjuvant therapy is to be considered for all patients with early invasive breast cancer after surgery. However this 'one size fits all approach' leads to a proportion of patients being over- or under treated as the risk of recurrence is difficult to determine. The advancements in molecular diagnostics are starting to improve the prognosis and treatment of breast- and other cancers. MammaPrint is a molecular diagnostic based on analyzing the entire human genome. Agendia’s solution therefore enables better clinical decisions, reducing over- and under-treatment and therefore leading to better health outcomes and less costs.

MammaPrint can be used for all early stage breast cancer patients, which is unique in the field of breast cancer recurrence tests. As MammaPrint will be developed for more accurately identifying which breast cancer patients will gain the most benefit of adjuvant chemotherapy, the potential market for introducing MammaPrint is worldwide. In order to reach this full scale adoption, this project is focused to achieve the last clinical evidence for the clinical utility of this test needed for the uptake in EU and US clinical guidelines and reimbursement arrangements. This uptake is necessary for adoption of MammaPrint by physicians worldwide.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › surgery
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• medical and health sciences › health sciences › infectious diseases › RNA viruses › HIV
• medical and health sciences › clinical medicine › oncology › breast cancer
• natural sciences › biological sciences › genetics › genomes

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• PHC-12-2014 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-2-2014

Finanzierungsplan

SME-2 - SME instrument phase 2

Koordinator

AGENDIA NV

• Netto-EU-Beitrag: € 4 048 407,00
• Adresse: RADARWEG 60 ; 1043 NT AMSTERDAM ; Niederlande
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  West-Nederland › Noord-Holland › Groot-Amsterdam
• Region: West-Nederland › Noord-Holland › Groot-Amsterdam
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 4 048 407,00